Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 3/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.35 |
| ▸ | CYP17A1 | P05093 | 3/20 | 0.35 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23689570 | 0.78 | SLC6A2 (0.42) | SLC6A2MAPTLMNAMAPK1CYP3A4 | |
| SCHEMBL3424021 | 0.78 | SLC6A2 (0.42) | SLC6A2MAPTLMNAMAPK1CYP3A4 | |
| SCHEMBL24919761 | 0.77 | MAPT (0.41) | SLC6A2MAPTLMNACYP3A4CYP2C19 | |
| Hydrochloric Acid SCHEMBL16774806 | 0.77 | SLC6A2 (0.41) | SLC6A2MAPTLMNAMAPK1CYP3A4 | |
| SCHEMBL16919627 | 0.76 | SLC6A2 (0.44) | SLC6A2MAPTLMNAMAPK1CYP3A4 | |
| SCHEMBL23095174 | 0.75 | ADRB2 (0.45) | SLC6A2LMNAMAPK1SLC6A4SLC6A3 | |
| SCHEMBL9283159 | 0.75 | ALDH1A1 (0.42) | SLC6A2MAPTLMNAALDH1A1SLC6A3 | |
| SCHEMBL9229402 | 0.75 | ALDH1A1 (0.42) | SLC6A2MAPTLMNAALDH1A1SLC6A3 | |
| SCHEMBL10808259 | 0.72 | SLC6A2 (0.41) | SLC6A2MAPTLMNAMAPK1CYP3A4 | |
| SCHEMBL3741345 | 0.72 | DPP4 (0.44) | SLC6A2MAPTLMNAMAPK1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230024302-A1 | 2,3,5-TRISUBSTITUTED PYRAZOLO[1,5-A]PYRIMIDINE COMPOUNDS | ARCUS BIOSCIENCES, INC. | 2023-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230024302-A1 | 2,3,5-TRISUBSTITUTED PYRAZOLO[1,5-A]PYRIMIDINE COMPOUNDS | PIK3CA, PIK3CG, PIK3CD | SLC6A2 4879/4885MAPT 3674/4885LMNA 4493/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.